top of page

Case Study: 4D Pharma

The Brief

4D Pharma engaged IB Communications to develop media interest in live biotherapeutics and 4D pharma as well as support  the positioning of the microbiome space as a serious therapeutic topic. This activity would tie into a wider communications activity leading up to, and in support of the their expected IPO.

Agency’s strategy involved communication in support of 4D pharma’s: 

  1. Technology: Products, therapeutic pipeline, technology platform, etc. Initial focus: Oncology pipeline and any successful research

  2. Management: Raising profile of senior leadership team/spokespeople). Initial Focus: Establish Duncan Peyton as the flagship of 4D brand, with other key spokespeople in support

  3. Corporate communications: Building the reputation, visibility, perception for the 4D brand. Initial focus: Investment fund close 


Key objectives:

  1. Support industry/opinion leading position within live biotherapeutics 

  2. Increase share of voice and monitor against key competitors

  3. Support the development of positive brand personalities and perceived expertise for spokespeople and senior management

  4. Target agreed stakeholders, including science, big pharma, investors, US focus

  5. Develop understanding of 4D key messages, and scientific differentiators within life sciences community

  6. Increase communication of positive milestones and strength of newsflow 

  7. Target top tier life sciences media, including Fierce, STAT, Biocentury, GEN and Endpoints, as well as national news and business press, ie Wall Street Journal.




All KPIs exceeded. Regular coverage gained in top tier titles, over and above competitors. Regular placement of exclusive profile pieces. Exceptional relationships build with GEN and Biopharma Report, in which 4D have been extensively covered several times.

Magazine logos depicting which titles IB Communications have placed articles for 4D Pharma


National News and Business Press. WSJ - 4D’s NASDAQ listing and Daily Mail - 4D’s Covid 19 trial.


4D pharma requested national news coverage for their Covid 19 trial, as well as specifically asking for WSJ coverage for their SPAC Nasdaq listing. IB Communications all ways goes above and beyond to meet client expectations.


To note, the agency has a specific US & UK/European service to enable businesses that want to focus on reaching specific regions/states within the US and English speaking regions.

Wall Street Journal webpage clipping
mailonline webpage clipping

Life sciences media: Biopharma Reporter.

At IB Communications we are creative in our approach to making news. This article came from media relations; we regularly brainstorm story angles and pitch them to our journalist contacts. We're particularly proud of the fact that once published, this story was highlighted a couple of weeks later, as the “most

popular story”, read by BioPharma’s audience - in second was J&J's vaccine news at the height of Covid. 

biopharma reporter webpage clipping
Biopharma reporter webpage clipping
Genetic Engineering & Biotechnology News  webpage clipping

Life sciences media. GEN

IB Communications work hard to develop long term relationships for our clients, providing increased opportunities over the term.  

Genetic Engineering & Biotechnology News Logo
Genetic Engineering & Biotechnology News  webpage clipping
Genetic Engineering & Biotechnology News  webpage clipping
Genetic Engineering & Biotechnology News  webpage clipping
Genetic Engineering & Biotechnology News  webpage clipping
Genetic Engineering & Biotechnology News  webpage clipping
4D Pharma Logo

IB Communications is able to provide regular opportunities for involvement in large industry relevant articles, involving interviews, Q&A’s and authored articles. This recent article for our client 4D pharma started with pitching for an editorial opportunity, that led to an interview and the ability for the client to approve copy before going to press.

An important profile piece that allowed the client to reset its brand proposition; detailing its scientific approach, product portfolio and key messages.  

bottom of page